MRNA Stock Price Today (October 2026) — Moderna, Inc. Analysis & Key Metrics 2026-10-07
Moderna, Inc. (MRNA) is trading at $196.48, up 4.81% today (as of October 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $120.67 (38.6% downside).
- Volatility is high (70.31% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: steady revenue (2.10% YoY) alongside competitive pressures in the Biotechnology space.
MRNA Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Moderna, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $74.59B
P/E Ratio
Forward P/E: N/A
Revenue Growth
Year over Year
Analyst Target
-38.6% downside from target
Key Investor Questions About MRNA
What investors need to know before buying
Based on current market data, MRNA presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 62.35)
- Fundamentals say: Mixed signals (nuanced financial profile)
MRNA's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for MRNA investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $1.29B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, MRNA stock traded between $22.28 and $208.90 and currently trades near the high end of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 70.31% annualized volatility and β=2.08, the stock exhibits high sensitivity to market moves—making MRNA suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
Moderna (MRNA) concluded the recent trading session at $198.88, signifying a +2.08% move from its prior day's close.
MRNA, PGEN Stocks Hit Multi-Year Highs – What’s Driving The Momentum Today?
Fresh analyst commentary put the spotlight on Moderna’s expanding mRNA cancer pipeline and Precigen’s transition into a commercial-stage biotech following the FDA approval of Papzimeos.
Moderna CEO’s Realistic Approach to Innovation
Moderna’s share price popped in August on positive news about its therapeutic cancer vaccine to prevent melanoma from recurring. At Journal House, United Nations General Assembly yesterday, the Journal’s Cynthia Koons asked CEO Stéphane Bancel: Why not enter oncology sooner? Bancel’s answer was a case study in making reasonable bets when the stakes are high.
Moderna Stock Jumped 7% Thursday. The Real Test Comes at ESMO on October 24.
Key TakeawaysOncology Repricing: Moderna stock jumped 7% on Thursday, September 24, closing at $195 as investors kept betting on intismeran autogene’s Phase 3 melanoma data due at ESMO on October 24. Street Split: The 23 analysts covering Moderna stock are split 4 buys, 1 outperform, 16 holds, 1 underperform, and 1 sell, with a mean target of $120 that sits 39% below Thursday’s close.
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
Five smaller stocks with market caps above $100 million beat MRNA’s monthly gain: INDP rose 249%, CYPH 124%, MNOV 85%, GRAL 58% and SRZN 53%.
Moderna Inc. (MRNA) Holds High-Level Investment Talks With UAE, Soars to 4-Year Peak
Moderna Inc. (NASDAQ:MRNA) saw its share price climb to a new four-year high on Thursday, as investors cheered news that it was exploring investment opportunities in the Middle East. In intra-day trading, the stock climbed to a record high of $195.71 before trimming gains to finish the session just up by 6.98 percent at $194.82 […]
From $63 To $195: Moderna’s Two-Month Rerating Isn’t Done
The stock was most recently helped by the company CEO’s optimism on its potential outside of COVID vaccines.
Moderna's View of the Global Pharma Industry
Chief executive Stéphane Bancel shares what’s next for Moderna after its report of a breakthrough of its cancer vaccine. He also discusses the state of the FDA and competition from China, AI integration in the drug industry and bioterrorism readiness.
Moderna (MRNA) Tied To AI Drug Push As Bob Langer Takes New Advisory Role
Moderna (NasdaqGS:MRNA) co-founder Bob Langer has joined the scientific advisory board of Cellular Intelligence, a biotech focused on AI-driven drug development. The appointment aligns with Cellular Intelligence's recent acquisition of a Parkinson's cell therapy program, linking AI discovery with advanced neurology research. Langer's role connects Moderna's mRNA expertise with a growing network of AI medicine collaborations involving Cellular Intelligence and its new Parkinson's therapy...
Moderna (MRNA) Stock Looks Very Expensive As Shares Surge Over 1 Year
Moderna has delivered a very large 1 year share price gain, which puts fresh attention on a basic question. Is the current valuation of the stock supported by the company’s sales profile rather than just recent momentum and headlines? The stock is up a very large amount over the past 12 months, which makes the link between Moderna’s market value and its underlying sales more important for anyone thinking about valuation risk. News around mRNA products, from the mFlusiva flu vaccine launch to...
Explore More Analysis for MRNA
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 29, 2026 (before the open)
Frequently Asked Questions
Common investor questions about Moderna, Inc.
Moderna, Inc. (MRNA) is currently trading at $196.48. The RSI (14-day) is at 62.4, indicating neutral territory. Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $120.67 implies 38.6% downside from current levels. Volatility is high at 70.3% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Moderna, Inc. (MRNA): The trailing P/E ratio is not available (the company may not be profitable). Price-to-Book is 8.66. Price-to-Sales is 26.29. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 18 analysts covering MRNA, the consensus price target is $120.67. This represents a 38.6% downside from the current price of $196.48. The range spans from a low target of $45.00 to a high target of $170.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Moderna, Inc. (MRNA) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Moderna, Inc. (MRNA) investors include: 1. High volatility (70.3% annualized)—the stock can experience significant daily price swings. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Elevated short interest (10.1% of float) suggests significant bearish sentiment. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Moderna, Inc.'s (MRNA) current debt and financial health profile: Total debt stands at $1.29B. The debt-to-equity ratio is 0.19x, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 2.30, indicating strong short-term liquidity. The quick ratio is 2.07. The company holds $5.14B in cash and equivalents. Free cash flow is positive at $299.25M, providing a cushion for debt servicing and shareholder returns.